PINE BROOK, N.J., Sept. 18 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately held biopharmaceutical company developing antibody-based therapies for the treatment of life-threatening infectious diseases, today announced the appointment of Robert D. Love as Chief Financial Officer.
Elizabeth G. Posillico, Ph.D., President and Chief Executive Officer, commented on the appointment, “Bob brings a wealth of expertise in corporate finance, operations and investor relations to Elusys. We are extremely pleased that he has joined the company as part of the senior management team.”
Mr. Love has more than 30 years of financial management experience at both privately held and publicly traded biopharmaceutical corporations. Most recently, he served as Executive Vice President and Chief Financial Officer of Alfacell Corporation, a biopharmaceutical company developing novel therapeutics for cancer and other life-threatening diseases. Previously, Mr. Love served as Senior Vice President, Chief Financial Officer and Chief Operating Officer of Trigenesis Therapeutics, a privately held dermatology company.
Prior to his work at Trigenesis, Mr. Love served as Senior Vice President, Business Partnering and Senior Vice President, Finance and Acquisitions at Quintiles Transnational Corporation/Innovex. Mr. Love also held several senior management positions at SmithKline Beecham, including Vice President and Director, Strategic Product Development and Vice President, and Chief Financial Officer in the United Kingdom. Mr. Love began his career in 1972 as an accountant at Coopers and Lybrand. He earned a B.A. in Accounting from Rutgers University and an M.B.A. in Finance and Marketing from Villanova University.
About Elusys
Elusys is a privately held biopharmaceutical company focused on the development of antibody-based therapeutics for the treatment of life- threatening infectious disease. In March of 2007, the company’s anthrax antibody therapeutic, Anthim(TM), was selected to R&D Directions’ list of “100 Great Investigational Drugs.”
Current venture investors include Essex Woodlands Health Ventures LLC, Invesco Private Capital, Crescendo Ventures, MedImmune Ventures and Pfizer. For more information please visit www.elusys.com.
Elusys Therapeutics, Inc.
CONTACT: Tim Allison of LaVoie Group, +1-978-745-4200, ext. 102,Tallison@lavoiegroup.com, for Elusys Therapeutics, Inc.
Web site: http://www.elusys.com/
